Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You too g18 have a Great One!!!
Breaking $1 now ?
Holy cow
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174809512
.
SGMO...88...Hit $1.14...HOD...🥳Those 30/40/50 Buys looking solid here...
georgie18
Member Level
Re: None
Wednesday, July 10, 2024 9:24:02 AM
Post#
381804
of 382120
SGMO...33...Looks Like a Reversal setting up here... https://schrts.co/fxvIUFMa ...Adding here...🥳
Currently there is no cure for hemophilia. But Pfizer is devoted to finding one.
Uhhhhhhhhhhhhhhhhhhh ... SGMO! https://www.hemhorizonhcp.com/?utm_source=GOOGLE&utm_medium=paidsearch&utm_campaign=71700000118640400&utm_content=43700080051646180&utm_term=hemophilia%20remedy&gad_source=1&gclid=EAIaIQobChMI2ravhP3EhwMV007_AR1VQg7LEAAYASAAEgJHM_D_BwE&gclsrc=aw.ds
I agree!!! As I am just getting back into trading after a lot of years and it means a lot to me and I’m sure others as well who read your posts on this board!!!
NP . That's what we should ALL be doing on these boards .
Ok I appreciate everything molee!!!
I don't think they have received notice yet . Better to be safe .
I got ya, sounds like a great plan , and again Thank You so much!!! How long do they have to retain the above $1 to remain on the Nasdaq?
As shorts cover and then reopen their shorts there will be lots of ups and downs .
Hold onto some of this as long term I think they will be okay .
Key is for them to re-attain the $1 threshold for compliance .
Enjoy the weekend >> M
Ok and thanks so much!!! Really helps me out on what you replied , thanks again !!! Best of everything to you!!!
2 years ago this was trading at $5 . The climb back up there will take time .
Revenues from Pfizer will accelerate the climb.
My trading plan is to keep a "core" amount locked up and other lots that I "trade" .
Good luck to you in your trading >> M
Anything under $1.00 will be CHEAP in days to come.
SGMO: Great Morning & More to come.
It’s looking good, hey molee, do you have any price targets in mind?, and I saw the $5 dollar prediction by the one individual from was it The Wainright Firm!!! And GLTUA!!!
Broke over .70 again, so the Algo's kick in. lol
SGMO is starting to act just like it did back in February when it ran.
(Only THIS time it has some Pfizer endorsement to add ADDITIONAL upside fuel, as well as advancement in it's research - trials).
$SGMO >> FWIW >
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics ( SGMO ) with a Buy and maintains $5 price target.
Nice follow up volume...🥳
22M by Noon. Not near yesterday's volume, but still constant flow and a much more sustainable angle of assent IMO.
SGMO...6065...Red to Green here...🥳
MM's offered some great discount prices P/M. ($.50's). This is easy a $1.00+ with a bit of patience IMO.
I am amused to see you post so confidently given your limited knowledge on the bio space.
If their funds werent enough to finish the job, Pfizer would have injected cash. They dont need the cash and thus there are only milestone payments.
This company is looking to launch! And that will be the narrative here until their BLA and MAA submission in early 2025.
let them sell some shares... if its a solid name.. it helps the company. Silly geese wouldnt get it.
Another AAV darling likely making it to market --- They work.. Ego traders on this board are too busy attacking each other and cant see the forest for all the trees.
"Giroctocogene fitelparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV6 capsid and a modified B-domain deleted human coagulation FVIII gene."
"Sangamo is eligible to earn from Pfizer up to $220 million in milestone payments upon the achievement of certain regulatory and commercial milestones for giroctocogene fitelparvovec and product sales royalties of 14% - 20% if giroctocogene fitelparvovec is approved and commercialized, subject to certain reductions."
After checking the .gov site for this trial this morning, I click on a tab that really highlighted the importance of this trial.
Check out all the countries involved: https://clinicaltrials.gov/study/NCT04370054?tab=history&a=32#version-content-panel
What’s up PT why do you say $3.00 TIA!!!! And GLTUA!!!
SGMO: "$2.00 is coming", you say??? (Whelp, maybe for to a MICRO-TINY-SMALL-FIRES at McDonald's --- for next year's 4th-of-July lunch special!!!)
SGMO: The BEST post to iHub that I have ever seen, Dude!!!!
SGMO: And this particular Firm ALWAYS does, Dude!!!! (And just watch, TOMORROW they will PR about a big, fat, REVERSE SPLIT!!! Or even MORE shares tossed to the Market!!!)
SGMO: It's that 170-Million FLOAT, Peeps!!! That will FOREVER hold this puppy BACK!!! (If this had a REASONABLE Float of let's say 4-Million, well, then this puppy would be circa $15 at least today --- the minute it divulged that it had ANYTHING to do with that Big Pharma Firm!!!)
Dang i hope not , hey p you think they are?
geez company dumping
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |